Clinical Group
RSS Feeds Peertechz

Global Journal of Cancer Therapy

    Abstract

    Open Access Mini Review PTZAID:GJCT-2-107

    Bortezomib in Anti-Cancer Activity: A Potential Drug

    Rajagopal Appavu* and Deepa Mohan

    26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppression, DNA replication, inflammation, and apoptosis. So, proteasome inhibition is a target therapy for cancer to promote cell cycle arrest or apoptosis. Bortezomib (Velcade®, PS-341, and Millennium Pharmaceuticals, Inc.) is the first, selective, reversible, and only proteasome inhibitor for the treatment of multiple myeloma have been approved by U.S. Food and Drug Administration (FDA) in 2003. Bortezomib downregulates the interaction of multiple myeloma cells with bone marrow stromal cells, inhibits angiogenesis, and blocks cell cycle progression. Clinically, continuous dosage of bortezomib leads to few side effects.

    Keywords:

    Published on: Mar 8, 2016 Pages: 5-8

    Full Text PDF Full Text HTML DOI: 10.17352/gjct.000007 CrossMark

    Find more...

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on GJCT